934481-43-3

Basic information

• Product Name: TERT-BUTYL 4-AMINO-3-METHYLBENZOATE
• Synonyms: TERT-BUTYL 4-AMINO-3-METHYLBENZOATE
• CAS NO: 934481-43-3
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.26888
• Mol File: 934481-43-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: TERT-BUTYL 4-AMINO-3-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-AMINO-3-METHYLBENZOATE(934481-43-3)
• EPA Substance Registry System: TERT-BUTYL 4-AMINO-3-METHYLBENZOATE(934481-43-3)

Safety Data

• Hazardous Substances Data: 934481-43-3(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-amino-3-methylbenzoate is a chemical compound commonly used as a UV absorber in sunscreens and other personal care products. It belongs to the family of benzoate esters and is derived from 4-amino-3-methylbenzoic acid and tert-butyl alcohol. TERT-BUTYL 4-AMINO-3-METHYLBENZOATE is known for its ability to absorb and dissipate UV radiation, protecting the skin from harmful sun damage. It is considered safe for use in cosmetics and has been extensively studied for its efficacy and safety profile. Tert-butyl 4-amino-3-methylbenzoate is often included in sunscreen formulations to provide broad-spectrum protection against both UVA and UVB rays.

Upstream product

• 2486-70-6 4-amino 3-methylbenzoic acid 
• 75-65-0 tert-butyl alcohol 
• 147290-67-3 tert-butyl 3-methyl-4-nitrobenzoate 

Downstream Products

• 1567846-75-6 C₃₄H₃₃N₇O 
• 1567846-74-5 C₂₉H₂₉N₃O₃ 

Relevant articles and documents

Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists

Identification of indazole derivatives acting as dual angiotensin II type 1 (AT1) receptor antagonists and partial peroxisome proliferator-activated receptor-γ (PPARγ) agonists is described. Starting from Telmisartan, we previously described that indole derivatives were very potent partial PPARγ agonists with loss of AT1 receptor antagonist activity. Design, synthesis and evaluation of new central scaffolds led us to the discovery of pyrrazolopyridine then indazole derivatives provided novel series possessing the desired dual activity. Among the new compounds, 38 was identified as a potent AT1 receptor antagonist (IC50 = 0.006 μM) and partial PPARγ agonist (EC50 = 0.25 μM, 40% max) with good oral bioavailability in rat. The dual pharmacology of compound 38 was demonstrated in two preclinical models of hypertension (SHR) and insulin resistance (Zucker fa/fa rat).

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5 and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds. [image]